One in ten emergency patients with blood in their urine dies within three months

Ten percent. That's the proportion of emergency department patients with visible blood in their urine who die within three months of showing up at the hospital. One in four of them has cancer. And right now, there are no evidence-based guidelines telling doctors what to do about it.

The WASHOUT study, the largest research effort ever conducted on this patient population, was presented at the European Association of Urology Congress (EAU26) in London. Its core finding is as straightforward as it is urgent: a CT scan or cystoscopy within 48 hours of arrival dramatically improves outcomes.

A common problem falling through the cracks

Roughly 25,000 people visit UK emergency departments each year with visible hematuria - blood in the urine. Globally, the numbers are much larger. These patients tend to be seriously unwell, but because hematuria is a symptom rather than a diagnosis - it can signal anything from a urinary tract infection to advanced bladder cancer - there's no standardized protocol for evaluation.

The result is a lottery. According to the WASHOUT study's global data, only about 53% of these patients receive a scan. Just 35% undergo surgery. Others are discharged home or admitted for observation, depending on which hospital they visit, which doctor they see, and what resources happen to be available.

8,500 patients, 380 hospitals, 90 days of follow-up

The study tracked more than 8,500 patients across 380 hospitals worldwide, following each person for 90 days after their emergency presentation. Researchers adjusted for confounding factors including age, frailty, and pre-existing conditions.

The findings are stark. Patients who received investigative tests - a CT scan or cystoscopy to look inside the bladder - within 48 hours of arriving at the emergency department fared significantly better on multiple measures. When cancer was present, patients scanned within that window received their diagnosis within one day on average. Those discharged without investigation waited an average of three weeks for diagnosis.

Patients who didn't receive timely tests or appropriate treatment were 2.5 percentage points more likely to die within three months compared to those who did. They also spent more time in hospital and were more likely to be readmitted with the same problem within 90 days.

Cancer is hiding in one out of four cases

Perhaps the most important number in the study: approximately 25% of emergency patients with visible blood in their urine had an underlying cancer, with bladder cancer being the most common. That's a strikingly high prevalence for a symptom that is sometimes treated casually in busy emergency departments.

Nikita Bhatt, a consultant urologist at St Vincent's University Hospital in Dublin who led the research, emphasized that too often these patients fall through the gaps because their symptom isn't obviously tied to a specific disease. The study's message to patients is equally direct: if you have visible blood in your urine, don't ignore it. See a doctor promptly, and if the symptom persists, keep pushing until you have an answer.

Toward evidence-based guidelines

The research team is working to incorporate these findings into clinical guidelines that would standardize the approach to emergency hematuria. Currently, the absence of such guidelines means that outcomes depend heavily on local practice patterns rather than evidence.

Joost Boormans, a urologist at Erasmus University Medical Center in Rotterdam and member of the EAU Scientific Congress Office, acknowledged the challenge of drawing condition-specific conclusions from a diverse patient population - hematuria has many possible causes. But he called the study an important demonstration that timely investigative tests reduce readmission risk and shorten hospital stays, both of which are significantly elevated in this population.

Patient advocate Jacqueline Emeks, who was diagnosed with a kidney infection and sepsis after presenting at the emergency department with blood in her urine, stressed that the findings should mean quicker triage, earlier investigations, and faster treatment for patients.

The study has clear limitations. It is observational, not a randomized trial, meaning it cannot definitively prove that early scanning caused better outcomes rather than reflecting that healthier patients were more likely to be scanned. The diverse mix of underlying conditions in the patient population makes it difficult to draw precise conclusions about any single disease. And translating a global study into specific national guidelines requires adapting to different healthcare systems and resource constraints.

But the scale of the problem - tens of thousands of emergency visits annually in the UK alone, with a 10% three-month mortality rate and 25% cancer prevalence - argues for action even while the evidence base continues to grow.